Harrow, Inc. HROW
29.37 USD -0.99 (-3.26%)
At closeNov 11, 2026, 6:21 PM EST
29.40 +0.03 +0.10%
After hours · Nov 11, 6:21 PM ET
28.60 Day range 30.52
25.76 52-week range 54.85
- YTD
- -40.06%
- 1 year
- -24.19%
News
seekingalpha.com Harrow, Inc. (HROW) Q3 2026 Earnings Call Transcript Harrow, Inc. ( HROW ) Q3 2026 Earnings Call November 10, 2026 8:00 AM EST Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO, Chairman of the…
marketbeat.com Harrow Q3 Earnings Call Highlights Harrow NASDAQ: HROW reported record third-quarter revenue and reaffirmed its full-year sales forecast, but sharply reduced its adjusted earnings outlook as lower-than-expected margins and accelerated…
benzinga.com AAON, Ziprecruiter, Rackspace Technology, Babcock & Wilcox And Other Big Stocks Moving Higher On Tuesday U.S. stocks fell, but AAON surged 23% on strong earnings and raised guidance. ZipRecruiter, Securitize and Senseonics led other gainers.
benzinga.com Harrow Q3 2026 Earnings Call Transcript Harrow (NASDAQ:HROW) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings…
zacks.com Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Harrow (HROW) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
zacks.com Harrow (HROW) Q3 Earnings Lag Estimates Harrow (HROW) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.33 per share a year ago.
benzinga.com Harrow Affirms FY2026 Sales Guidance of $350.000M-$365.000M vs $349.747M Est Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000 million-$365.000 million vs $349.747 million estimate.
benzinga.com Harrow Q3 EPS $0.25 Beats $0.22 Estimate, Sales $99.297M Beat $98.501M Estimate Harrow (NASDAQ:HROW) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.22 by 13.64 percent. This is a 24.24 percent decrease over earnings of $0.33 per…
globenewswire.com Harrow Announces Third Quarter 2026 Financial Results Third Quarter 2026 and Selected Highlights: Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year Branded revenue of $83.5 million, up 62% year over year and…
zacks.com Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy? Harrow (HROW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
businesswire.com PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow's Eye Care Portfolio SCOTTSDALE, Ariz.--(BUSINESS WIRE)--PHIL Inc., the technology-powered patient access platform, today announced its partnership with Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease…
globenewswire.com Harrow Launches HarrowRx Platform NASHVILLE, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of HarrowRx, a…
seekingalpha.com Harrow's Top Two Drugs Alone Can Justify Its Current Valuation Harrow trades at a 52-week low due to management miscommunication and short-term revenue volatility, but its fundamentals remain robust. Vevye and Iheezo, Harrow's flagship drugs, both address large,…
globenewswire.com Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026 NASHVILLE, Tenn., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its…
zacks.com Do Options Traders Know Something About Harrow Stock We Don't? Investors need to pay close attention to HROW stock based on the movements in the options market lately.
defenseworld.net Harrow (NASDAQ:HROW) Stock Keeps Buy Rating at BTIG Research Harrow (NASDAQ: HROW - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at BTIG Research in a research note issued to investors on Wednesday, Benzinga reports. They…
globenewswire.com Harrow Closes Acquisition of TYRVAYA® First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise First and Only FDA-Approved Nasal Spray for…
defenseworld.net Harrow, Inc. (NASDAQ:HROW) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, Marketbeat.com reports. One…
globenewswire.com Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific…
defenseworld.net Harrow (NASDAQ:HROW) Stock Falls 6.8% – Here’s Why Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) dropped 6.8% during trading on Monday. The company traded as low as $31.64 and last traded at $30.8280. Approximately 176,792 shares were…
defenseworld.net Head-To-Head Contrast: Harrow (NASDAQ:HROW) & Supernus Pharmaceuticals (NASDAQ:SUPN) Harrow (NASDAQ: HROW - Get Free Report) and Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two…
benzinga.com Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
benzinga.com Leerink Partners Initiates Coverage On Harrow with Outperform Rating, Announces Price Target of $45 Leerink Partners analyst Daniel Clark initiates coverage on Harrow (NASDAQ:HROW) with a Outperform rating and announces Price Target of $45.
globenewswire.com Harrow to Participate in Three Investor Conferences in September NASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Harrow's Iheezo Cuts Eye-Injection Discomfort by More Than Half Ophthalmic disease management company Harrow Inc. (NASDAQ:HROW) on Thursday shared outcomes from a prospective, randomized, contralateral-eye clinical study.
benzinga.com Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half Harrow (NASDAQ: HROW) posts positive study results for IHEEZO ophthalmic gel, significantly reducing IVT injection patient discomfort.
benzinga.com Harrow Reports Statistically Significant Results Favoring IHEEZO In Intravitreal Injection Study Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced positive results from a prospective, randomized, contralateral-eye study…
globenewswire.com Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest…
benzinga.com OppFi Posts Downbeat Q2 Earnings, Joins Upwork, Rocket Lab And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures mostly lower. OppFi (OPFI) shares fall after missing Q2 earnings and cutting FY26 guidance. Other stocks also down in pre-market.- benzinga.com Harrow Affirms FY2026 Sales Guidance of $350.000M-$365.000M vs $348.468M Est Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000 million-$365.000 million vs $348.468 million estimate.
benzinga.com Harrow Q2 EPS $(0.46) Misses $(0.21) Estimate, Sales $70.661M Beat $70.342M Estimate Harrow (NASDAQ:HROW) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.21) by 119.05 percent. This is a 453.85 percent decrease over earnings of $0.13…
benzinga.com Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook Viatris sells Tyrvaya to Harrow for up to $100 million, raises 2026 guidance after second-quarter earnings and revenue beat estimates.- benzinga.com Samsung Bioepis, Harrow Present SB11 Safety Data At ASRS 2026 Annual Meeting; Interim PMS Study Shows SB11 Comparable To Lucentis A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumabIn treatment-naïve patients, SB11 provided functional…
- benzinga.com Harrow Presents Three Studies Supporting IHEEZO, Low Viscosity Ocular Anesthetic Gel, And BYOOVIZ, FDA-Approved Biosimilar Referencing LUCENTIS At ASRS 2026 Annual Meeting Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting IHEEZO® (chloroprocaine HCl…
benzinga.com 8 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Harrow Announces Commercial Launch Of BYOOVIZ, FDA-Approved Biosimilar Referencing LUCENTISi And Developed By Samsung Bioepis Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar…
benzinga.com Harrow Adds Another Piece To Ophthalmology Strategy Harrow relaunches Verkazia for VKC treatment, targeting pediatric eye disease with a steroid-sparing therapy option.
benzinga.com Harrow Re-Launches Steroid-Sparing VERKAZIA For Vernal Keratoconjunctivitis, Targeting Underlying Inflammatory Mechanisms In Pediatric Patients VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access…
benzinga.com Alpha Buying: When CEOs and CFOs Buy Together - benzinga.com Cantor Fitzgerald Maintains Overweight on Harrow, Lowers Price Target to $88 Cantor Fitzgerald analyst Steve Seedhouse maintains Harrow (NASDAQ:HROW) with a Overweight and lowers the price target from $91 to $88.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Transcript: Harrow Q1 2026 Earnings Conference Call 
benzinga.com AST SpaceMobile Posts Downbeat Q1 Results, Joins Hims & Hers Health, Gitlab And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session U.S. stock futures lower, Nasdaq down 200 points. AST SpaceMobile shares dip 11% after reporting worse-than-expected financial results.
benzinga.com Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket Harmonic Inc (HLIT) rose in pre-market trading after beating earnings expectations & raising guidance. Other gainers include Buzzfeed, MacroGenics, & SI-Bone.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Harrow Affirms FY2026 Sales Guidance of $350.000M-$365.000M vs $351.380M Est Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000 million-$365.000 million vs $351.380 million estimate.
- benzinga.com Harrow Q1 EPS $(0.74) Misses $(0.39) Estimate, Sales $44.203M Miss $52.420M Estimate Harrow (NASDAQ:HROW) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.39) by 89.74 percent. This is a 94.74 percent decrease over losses of $(0.38)…
benzinga.com Earnings Scheduled For May 11, 2026